Thermo Fisher Scientific Inc (TMO) Fair Value & Analysis
Healthcare · US · Market cap $179B
Thermo Fisher Scientific Inc
TMO · US
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 8 days ago
Share price +8.6% over the past month.
Price vs Fair Value (12 months)
12‑month range $362.14 – $572.81 · fair‑value band $174.31 – $429.36 · the $469.35 price screens above the $326.81 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Thermo Fisher Scientific Inc (TMO) currently trades at $469.35, while our model-based Fair Value estimate is $326.81 — implying the stock looks roughly 30.4% overvalued today. We read business quality at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Thermo Fisher Scientific Inc generated revenue of $45.2B at a net margin of 15.2%. Revenue grew 6.2% year over year. It earns a return on equity of 13.5%. Net debt stands at $31.0B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Thermo Fisher Scientific Inc reported revenue of $44.6B in FY2025 versus $39.2B in FY2021, a compound +3.2%/yr. Reported net income was $6.7B in FY2025, compounding −3.4%/yr from FY2021.
Is TMO fairly valued? → Check now
Recent news
- Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026
- Microspheres Market Forecast to Hit USD 6.47 Billion by 2031 Amidst Rising Sustainability Regulations
- AustinPx Expands KinetiSol™ Technology Commercial Access through Thermo Fisher Scientific Collaboration
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Danaher Corporation DHR | $178.19 | $112.34 | -37% |
| 2359 2359 | HK$152.80 | HK$120.99 | -21% |
| WuXi AppTec Co WUXAY | $18.59 | $25.09 | +35% |
| IDEXX Laboratories, Inc IDXX | $556.94 | $255.77 | -54% |
| Lonza Group LZAGY | $61.53 | $15.70 | -74% |
| Agilent Technologies, Inc A | $126.49 | $63.09 | -50% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Thermo Fisher Scientific Inc (TMO) undervalued?
What is the fair value of TMO?
What is the quality score of TMO?
What is the revenue of Thermo Fisher Scientific Inc (TMO)?
What is the net profit margin of TMO?
Does Thermo Fisher Scientific Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.